What is the recommended first‑line systemic therapy for an adolescent with renal cell carcinoma metastatic to the pleura, and how should a symptomatic pleural effusion be managed?

First-Line Systemic Therapy for Adolescent RCC with Pleural Metastasis

For an adolescent with metastatic renal cell carcinoma to the pleura, cabozantinib monotherapy is the preferred first-line systemic treatment, and symptomatic pleural effusion should be managed with either indwelling pleural catheter (IPC) or talc pleurodesis as definitive first-line intervention.

Systemic Therapy Selection

Primary Recommendation: Cabozantinib

The 2024 ESMO guidelines establish cabozantinib as the preferred first-line monotherapy for advanced RCC in non-clear cell histologies, demonstrating progression-free survival advantage over sunitinib 1. While these guidelines don't specifically address adolescents, the evidence base supports this approach across age groups.

Alternative Considerations

If combination therapy is warranted based on disease burden or risk stratification:

• Pembrolizumab plus lenvatinib showed 49% objective response rate in prospective trials 1
• Cabozantinib plus nivolumab demonstrated 48% response rate 1

The combination regimens carry higher toxicity profiles but may be appropriate for:

• Intermediate to poor-risk disease by IMDC criteria
• Sarcomatoid features present
• Need for rapid disease control

Adolescent-Specific Context

Limited pediatric data exists, but one case report documents successful sequential use of tyrosine kinase inhibitors (sorafenib, sunitinib) in a 14-year-old with metastatic RCC, with manageable toxicity including hypothyroidism and hypertension 2. This supports the feasibility of TKI therapy in adolescents, though close monitoring for these specific adverse effects is essential.

Management of Symptomatic Pleural Effusion

Definitive Intervention Strategy

For symptomatic pleural effusion with expandable lung and no prior definitive therapy, either IPC or chemical pleurodesis with talc should be used as first-line management 3.

Decision Algorithm for Pleural Management:

Choose IPC if:

• Patient preference for outpatient management
• Desire to minimize hospital days (IPCs reduce total hospitalization time)
• Uncertain lung expandability
• Need for ongoing drainage flexibility

Choose talc pleurodesis if:

• Patient cannot manage home catheter care
• Concern about infection risk (pleurodesis has lower cellulitis rates)
• Confirmed expandable lung on imaging
• Single definitive procedure preferred

Technical Approach

• Talc delivery method: Either poudrage (via thoracoscopy) or slurry (via chest tube) are acceptable; no clear superiority demonstrated 3
• Avoid repeat thoracentesis: Definitive pleural procedures result in fewer subsequent procedures and complications compared to serial thoracentesis 3
• Timing: Perform definitive intervention after first reaccumulation rather than multiple temporizing thoracenteses

Critical Pitfalls to Avoid

1. Don't delay definitive pleural intervention: Only 24% of patients receive appropriate definitive procedures, leading to more emergency procedures and complications 3

2. Monitor for treatment-related toxicities in adolescents: Specifically watch for:

   • Hypothyroidism (common with TKIs)
   • Hypertension (particularly with bevacizumab and sunitinib) 2
   • Growth and development effects

3. Don't assume lung metastases: Pleural metastasis from RCC can occur without parenchymal lung involvement—this is rare (1-2% of malignant effusions) but documented 4

4. Rule out infection: In patients on immunotherapy, consider immune-related serositis with eosinophilic effusion, which may mimic malignant effusion 5

Coordination of Systemic and Local Therapy

Initiate systemic therapy (cabozantinib) concurrently with or shortly after pleural intervention. The pleural procedure should not delay systemic treatment initiation, as RCC is not typically chemoresponsive enough to obviate the need for mechanical pleural management 6.